Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2009. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by eight individuals on June 6, 2009, through the Company's Share Reward Plan. The purchase price was £10.47 per Ordinary share. The transactions involved both personal contributions (partnership element) and company contributions (matching element). Specific acquisitions included:
- Mr A P Witty: 12 shares (personal) and 12 shares (company match).
- Mr J S Heslop: 12 shares (personal) and 12 shares (company match).
- Mr S M Bicknell: 12 shares (personal) and 12 shares (company match).
- Mr E J Gray: 12 shares (personal) and 12 shares (company match).
- Mr S A Hussain: 11 shares (personal) and 11 shares (company match).
- Mr D Learmouth: 12 shares (personal) and 12 shares (company match).
- Mr D S Redfern: 12 shares (personal) and 12 shares (company match).
- Ms C Thomas: 12 shares (personal) and 12 shares (company match).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £10.47 per Ordinary share on June 6, 2009.
- Confirm the total number of shares acquired by each listed director under the Share Reward Plan.
- Review the terms of the Share Reward Plan to understand the matching contribution structure.
- Note that this filing contains no financial performance data for the period.